The main objective is to evaluate the decrease in crystalline volume of the target tophus using Dual-Energy Computed Tomography (DECT), after 6 months +/- 1 month of urate-lowering therapy with target uricemia. Study hypothesis * The dynamics of tophus resolution with urate-lowering therapy is poorly understood. * It is variable according to the location of the tophus, peri articular / intratendinous, but also probably at the feet / hands, the initial overall volume of the tophus, the initial crystal charge of the tophus. Knowledge of prognostic factors for tophus resolution will help determine the best target for treatment follow-up for each patient. * Erosions are the consequence of tophus. Tophus resolution could be associated with repair of erosions and stabilization of joint destruction.
Study design The research is a non-randomized prospective bi-centric study in adult patients with tophaceous gout. It aims at studying tophus resolution (main objective), and prognostic factors for tophus resolution (secondary objective), and bone erosions, with Dual-Energy Computed Tomography (DECT) (secondary objective). Study population * Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia \< 360µmol/L). * Recruitment of patients during a visit or hospitalization in rheumatology at Lariboisière Hospital. Calculated size of study population: 50 patients No control group Inclusion criteria * Age greater than or equal to 18 years * Patient with a tophaceous gout * Without urate-lowering treatment or with treatment but uricemia not at target * Having given its free and informed consent to participate in this study * Affiliated with a social security system Non-Inclusion criteria * Pregnant or breastfeeding woman * Participation in another intervention research or period of exclusion due to a previous research. * Impossibility to position oneself in ventral position (position for hands/wrists DECT acquisition). Acts or product added for the research study Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360µmol/L (baseline DECT is in the domain of usual care). For each patient, 3 visits (usual care): * M0: Inclusion visit * M6 + /- 1 month: visit, usual care, + DECT for research purpose * M12 + /- 1 month: visit, usual care, + DECT for research purpose Research duration: * Inclusion period: 24 months * Duration of participation (treatment + follow-up): 12 months + /- 1 month * Total duration: 37 months
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
50
Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
Radiology Department Lariboisière Hospital
Paris, Île-de-France Region, France
Reumatology Department Lariboisière Hospital
Paris, Île-de-France Region, France
the percentage of decrease in crystal volume of the target tophus
decrease in crystal volume of the target tophus detected using dual-energy CT compared to the volume at baseline
Time frame: after 6 months +/- 1 month of traitment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.